All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Venetoclax is a BCL2 inhibitor and is widely used to treat CLL patients. The aim of this study was to investigate the molecular and genetic mechanisms behind secondary venetoclax resistance, which is observed in heavily pre-treated CLL patients. The authors performed an in-depth genetic assessment with targeted-amplicon next-generation sequencing (NGS) of relapsed or refractory (R/R) CLL patients, who were treated with venetoclax on three early phase clinical trials.
Which population of patients with CLL might benefit most from venetoclax plus ibrutinib?
During the 61st ASH meeting in Orlando, US, the Lymphoma Hub were pleased to speak to Nitin Jain, MD Anderson Cancer Center, Houston, US. We asked: Which...
Fixed duration or MRD-guided venetoclax maintenance treatment in patients with CLL unfit for first-line FCR: Results from HOVON 139/GIVE trial
High rates of undetectable minimal residual disease (uMRD) have been documented in fixed-duration treatment...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox